Article Text

Download PDFPDF
Case report
ROS1-rearranged lung adenocarcinoma with peritoneal carcinomatosis on initial presentation
  1. Vera Kazakova1,
  2. Sylvia V Alarcon Velasco2,
  3. Aleksandr Perepletchikov3 and
  4. Christopher S Lathan4
  1. 1Department of Medicine, St Elizabeth's Medical Center, Boston, Massachusetts, USA
  2. 2Hematology/Oncology, Dana Farber Cancer Institute at St Elizabeth's Medical Center, Boston, Massachusetts, USA
  3. 3Pathology, St Elizabeth's Medical Center, Boston, Massachusetts, USA
  4. 4Hematology/Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
  1. Correspondence to Dr Vera Kazakova; vera.kazakova{at}


Peritoneal carcinomatosis (PC) is progression of the primary cancer to the peritoneum that is seen in only 1.2% of patients with lung cancer. It is associated with poor prognosis especially if present at the time of initial cancer diagnosis. The predisposing factors for peritoneal spread are not yet well understood. It has been suggested that the oncogene status of the tumour can influence the patterns of metastatic spread. There is not enough data about the role of c-ROS oncogene 1 (ROS1) mutation in the development of PC in non-small cell lung cancer. Here, we describe a case of a 56-year-old man who presented with new-onset ascites and was found to have PC. He was diagnosed with ROS1-rearranged lung adenocarcinoma. No obvious primary tumour was identified. Patient responded well to targeted therapy with crizotinib and remained 6 months free of disease progression.

  • lung cancer (oncology)
  • pathology
  • tyrosine kinase inhibitor
View Full Text

Statistics from


  • Contributors VK collected history and data, wrote the manuscript. SVAV and CSL participated in correcting the manuscript and writing discussion section. AP prepared the pathology slides, established the diagnosis and prepared images. All authors reviewed and approved the final version of the case report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.